Kite Pharma has added three experts in cancer immunotherapy to its scientific advisory board.
Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder Verma is chair of exemplary science and American Cancer Society professor of molecular biology at The Salk Institute.
Their expertise will help the US biotech develop medicines that activate the body’s T cells to fight tumours.
Cancer immunotherapies are becoming a popular method of treatment for investigation in oncology, with big deals involving the likes of Bayer, Merck Serono, GSK and Roche.
“Kite is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board,” said Dr Aya Jakobovits, president and CEO of Kite.